Ginkgo Bioworks (NYSE:DNA) Shares Up 5.9% – What’s Next?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)’s share price shot up 5.9% during mid-day trading on Tuesday . The stock traded as high as $7.71 and last traded at $7.71. 326,196 shares changed hands during trading, a decline of 72% from the average session volume of 1,149,581 shares. The stock had previously closed at $7.28.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DNA shares. BTIG Research upped their price objective on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a research report on Friday, August 23rd. The Goldman Sachs Group cut their price objective on Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. Finally, TD Cowen raised their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Ginkgo Bioworks has a consensus rating of “Hold” and a consensus price target of $4.16.

Ginkgo Bioworks Stock Up 1.3 %

Ginkgo Bioworks (NYSE:DNA) last posted its earnings results on Thursday, August 8th. The company reported ($3.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($3.20). The firm had revenue of $56.21 million for the quarter, compared to the consensus estimate of $41.46 million. Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 earnings per share for the current fiscal year.

Institutional Trading of Ginkgo Bioworks

Several institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in shares of Ginkgo Bioworks by 20.2% in the 1st quarter. Principal Financial Group Inc. now owns 132,302 shares of the company’s stock valued at $153,000 after acquiring an additional 22,201 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of Ginkgo Bioworks during the 1st quarter valued at $28,000. Swiss National Bank lifted its holdings in shares of Ginkgo Bioworks by 1.4% during the 1st quarter. Swiss National Bank now owns 2,078,500 shares of the company’s stock worth $2,411,000 after acquiring an additional 27,700 shares during the last quarter. Smith Salley Wealth Management boosted its holdings in shares of Ginkgo Bioworks by 125.0% in the 1st quarter. Smith Salley Wealth Management now owns 54,000 shares of the company’s stock worth $63,000 after purchasing an additional 30,000 shares in the last quarter. Finally, First Trust Direct Indexing L.P. purchased a new position in shares of Ginkgo Bioworks during the 1st quarter valued at about $35,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.